Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 702196, 9 pages
http://dx.doi.org/10.1155/2013/702196
Research Article

Bromelain Inhibits Allergic Sensitization and Murine Asthma via Modulation of Dendritic Cells

1Helen & Harry Gray Cancer Center and Department of Medicine, Hartford Hospital, 80 Seymour Street, P.O. Box 5037, Hartford, CT 06102-5037, USA
2Department of Medicine, University of CT Health Center (UCHC), Farmington, CT 06030, USA
3Department of Immunology, UCHC, Farmington, CT 06030, USA
4Department of Pediatrics, UCHC, Farmington, CT 06030, USA
5Department of Pathology, UCLA Immunogenetics Center, Los Angeles, CA 90095, USA
6Department of Allied Health Sciences, University of CT, Storrs, CT 06268, USA

Received 17 June 2013; Revised 12 August 2013; Accepted 19 August 2013

Academic Editor: Young-Rae Lee

Copyright © 2013 Eric R. Secor Jr. et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

In supplementary Table 1 toxicity parameters (liver function, bronchoalveolar lavage (BAL) protein analysis and total WBCs) determine that sBr treatment was not harmful over the three week treatment course. Supplementary Figure 1 determines that sBr treatment, throughout OVA/alum sensitization, did not alter the BAL cellular differential. In order to determine if the co-localization of i.p. sBr treatment and i.p OVA/alum sensitization resulted in the reduced allergic airway disease (AAD) the immunization and sBr treatment were separated. Supplementary Figure 2 provides data showing that sBr i.p. treatment still reduced BAL leukocytes at AAD, with subcutaneous OVA/alum sensitization. Supplementary Figure 3 depicts the general gating strategies for flow cytometry and Supplementary Figure 4 illustrates the reduction of DC subsets (in the mesenteric lymph nodes) when sBr is administered throughout OVA/Alum sensitization.

  1. Supplementary Materials